REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
29/06/2026
Voltar para busca
Dado oficial do USPTO
ÆTERNA ZENTARIS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
18
Atualização mais recente
29/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
01/09/2020
Data de registro
29/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/06/2021
Última transação
29/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Frankfurt am Main, DE
Examinador
JACKSON, STEVEN W
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized wavy line in the shape of a sideways infinity symbol on a slight tilt to the right with the tail ends in azure and the middle swoop in dark lime green followed by the word "ÆTERNA" in thin dark lime green letters above the word "ZENTARIS" in thick azure letters.
Titulares e representantes
Titulares
Æterna Zentaris GmbH
Representantes
Victoria Friedman DENNEMEYER & ASSOCIATES LLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic productsconjugated or notfor the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancerhormonal tumorshormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agentspreparations and substances for medical purposes; pharmaceutical productscomprising growth hormone secretagoguesghrelin receptor agonistsghrelin receptor antagonistsghrelin mimeticsgrowth hormone analoguesgrowth hormone fusion proteinsgrowth hormone releasing hormone analoguesauto immune modulating proteinstherapeutic antibodiessmall molecule kinase inhibitorsphospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical productscomprising small molecule kinase inhibitorsphospholipidstherapeutic antibodiesnatural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications
Publicações
Histórico de despachos e eventos da marca no USPTO.
18 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
29/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/04/2021
PUBO
PUBLISHED FOR OPPOSITION
13/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/03/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
10/03/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
05/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/02/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/01/2021
GNRT
NON-FINAL ACTION E-MAILED
12/01/2021
CNRT
NON-FINAL ACTION WRITTEN
12/01/2021
DOCK
ASSIGNED TO EXAMINER
06/01/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2020
NWAP
NEW APPLICATION ENTERED
04/09/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ÆTERNA ZENTARIS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.